Skip to main content

Animations

MJFF Publications

2631 - 2640 of 6431 Results
Title
Year
  • Year
  • 2020
  • 2020
  • 2021
  • 2021
  • 2023
  • 2023
  • 2021
  • 2012
  • 2015
  • 2022
  • Summary Details
    OPEN
    Title: Beyond PD-MCI: objectively defined subtle cognitive decline predicts future cognitive and functional changes
    Journal Name: Journal of Neurology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1007/s00415-020-10163-4
    Citation Count: 15
  • Summary Details
    OPEN
    Title: An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-191786
    Citation Count: 43
  • Summary Details
    OPEN
    Title: Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-212672
    Citation Count: 30
  • Summary Details
    OPEN
    Title: Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-212714
    Citation Count: 27
  • Summary Details
    OPEN
    Title: Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
    Journal Name: Journal of Parkinson’s Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-239901
    Citation Count: 62
  • Summary Details
    OPEN
    Title: Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where do we go from here?
    Journal Name: Current Neuropharmacology
    Publisher: Bentham Science Publishers Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.2174/1570159x21666230801140648
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Dystonia Responsive to Dopamine: POLG Mutations Should Be Considered If Sensory Neuropathy Is Present
    Journal Name: Journal of Movement Disorders
    Publisher: The Korean Movement Disorder Society
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc, cc-by-nc
    DOI - Digital Object Identifier: 10.14802/jmd.20159
    Citation Count: 10
  • Summary Details
    OPEN
    Title: GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0b013e3182735e9a
    Citation Count: 151
  • Summary Details
    OPEN
    Title: Large-scale assessment of polyglutamine repeat expansions in Parkinson disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000002016
    Citation Count: 27
  • Summary Details
    OPEN
    Title: Special Issue on new therapeutic approaches to Parkinson disease
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.108998
    Citation Count: 5
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.